Macrogenics Q4 2023 GAAP EPS $(0.750), Sales $10.720M Down From $73.099M YoY
Portfolio Pulse from Benzinga Newsdesk
Macrogenics (NASDAQ:MGNX) reported a Q4 2023 GAAP EPS of $(0.750) and sales of $10.720M, marking an 85.33% decrease from $73.099M in sales YoY.
March 07, 2024 | 9:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Macrogenics reported a significant decrease in sales and a loss per share in Q4 2023.
The reported loss per share and a substantial decrease in sales YoY are likely to negatively impact investor sentiment and potentially the stock price of Macrogenics in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100